| Mar'20 | Dec'19 | Sep'19 | Jun'19 | Mar'19 | Dec'18 | Sep'18 | Jun'18 | Mar'18 | Dec'17 | Sep'17 | Jun'17 | Mar'17 | Dec'16 | Sep'16 | Jun'16 | Mar'16 | Dec'15 | Sep'15 | Jun'15 | Mar'15 | Mar'14 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash flows from operating activities | |||||||||||||||||||||
Net loss | |||||||||||||||||||||
-9,687 | -7,450 | -5,731 | -7,674 | -4,924 | -5,240 | -6,600 | -6,672 | -3,551 | -4,085 | -6,099 | -5,172 | -5,222 | -3,644 | -3,807 | -3,692 | -3,586 | -5,090 | -4,736 | -7,865 | -5,711 | -228 |
Adjustments to reconcile net loss to net cash used in operating activities | |||||||||||||||||||||
Amortization of debt discount on notes payable | |||||||||||||||||||||
- | - | - | - | - | 0 | 0 | 146 | 258 | 259 | 256 | 337 | 431 | 431 | 431 | 524 | 400 | 240 | 240 | 240 | 171 | 6 |
Amortization of investment premiums (accretion of investment discounts), net | |||||||||||||||||||||
-636 | 500 | -161 | 37 | 101 | 217 | 5 | -87 | -62 | 16 | 30 | 18 | 31 | 36 | 31 | 36 | 48 | - | - | - | - | - |
Amortization of financing costs | |||||||||||||||||||||
45 | 46 | 40 | 30 | 30 | 30 | 30 | 30 | 30 | 34 | 17 | 422 | 98 | - | - | - | - | - | - | - | - | - |
Amortization of non-cash clinical trial costs | |||||||||||||||||||||
- | 0 | 0 | 6 | 134 | 125 | 64 | 252 | 225 | 346 | 248 | 358 | 42 | - | - | - | - | - | - | - | - | - |
Change in fair value of accrued license fees | |||||||||||||||||||||
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | -4,421 | -4,960 | - |
Change in fair value of debt conversion feature liability | |||||||||||||||||||||
- | - | - | - | - | 0 | 0 | 37 | 1,361 | 633 | -1,136 | 570 | 278 | 620 | -64 | 412 | 96 | -216 | -197 | -546 | -82 | 10 |
Stock-based compensation | |||||||||||||||||||||
1,652 | 976 | 811 | 922 | 1,034 | 617 | 750 | 631 | 610 | 363 | 345 | 341 | 402 | 358 | 320 | 490 | 624 | 527 | 601 | 1,471 | 0 | 0 |
Amortization of right-of-use assets | |||||||||||||||||||||
68 | - | - | - | 64 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest expense related to operating lease liability | |||||||||||||||||||||
10 | - | - | - | 13 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Realized (gain) loss on investments | |||||||||||||||||||||
-2 | 0 | -6 | 0 | 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Changes in operating assets and liabilities: | |||||||||||||||||||||
Prepaid expenses and other current assets | |||||||||||||||||||||
-569 | 6,670 | 175 | 610 | -75 | -1,686 | 427 | 1,080 | 316 | -198 | -245 | 167 | -221 | -181 | -108 | 203 | -187 | -424 | 912 | 576 | 15 | 7 |
Accounts payable | |||||||||||||||||||||
650 | 343 | 219 | 194 | 716 | -175 | -330 | 829 | -832 | 32 | 175 | -466 | 523 | 376 | -102 | -47 | 449 | 81 | 92 | 7 | 37 | 115 |
Accrued expenses | |||||||||||||||||||||
1,840 | 519 | 1,283 | 760 | -168 | 337 | 1,015 | 544 | -428 | -477 | 318 | 697 | 472 | 281 | 252 | 77 | -752 | 315 | 1,052 | 129 | 62 | 2 |
Lease liability | |||||||||||||||||||||
-83 | - | - | - | -27 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net cash used in operating activities | |||||||||||||||||||||
-4,302 | -11,743 | -3,398 | -6,459 | -3,152 | -2,679 | -5,503 | -5,270 | -5,303 | -3,947 | -3,329 | -4,202 | -3,280 | -2,464 | -2,654 | -3,226 | -2,725 | -3,299 | -3,400 | -1,620 | -410 | -100 |
Purchases of investments | |||||||||||||||||||||
56,435 | 80,048 | 99,474 | 83,666 | 99,218 | 180,914 | 53,583 | 81,428 | 32,279 | 9,420 | 2,680 | 4,369 | 6,057 | 4,658 | 2,016 | 10,097 | 149 | - | - | - | - | - |
Proceeds from maturities of investments | |||||||||||||||||||||
67,587 | 68,987 | 114,628 | 94,645 | 91,609 | 38,523 | 26,497 | 14,803 | 2,652 | 5,024 | 4,072 | 3,604 | 8,096 | 6,106 | 2,458 | 5,266 | 6,122 | - | - | - | - | - |
Net cash provided by (used in) investing activities | |||||||||||||||||||||
11,152 | -11,061 | 15,154 | 10,979 | -7,609 | -142,391 | -27,086 | -66,625 | -29,627 | -4,396 | 1,392 | -765 | 2,039 | 1,447 | 441 | -4,831 | 5,972 | - | - | - | - | - |
Proceeds from issuances of common stock, net of underwriting discounts and commissions | |||||||||||||||||||||
- | - | - | - | - | 0 | 165,205 | 72,580 | 58,822 | 14,520 | 1,250 | 4,042 | 2,540 | - | - | - | - | - | - | - | - | - |
Public offering and financing costs | |||||||||||||||||||||
- | - | - | - | - | 283 | 216 | 120 | 146 | 376 | 62 | 46 | 16 | 71 | 415 | 551 | 57 | 48 | 704 | 2,011 | 17 | - |
Value of shares withheld related to employee tax withholding | |||||||||||||||||||||
127 | 27 | 2 | 38 | 84 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Repurchases of common stock | |||||||||||||||||||||
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 |
Proceeds from warrant and option exercises and stock issuances under employee stock purchase plan | |||||||||||||||||||||
160 | - | 141 | 298 | 409 | - | 2,498 | 1,621 | 3,622 | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net cash provided by financing activities | |||||||||||||||||||||
33 | 229 | 73 | 260 | 325 | 343 | 167,485 | 70,149 | 62,298 | 14,763 | 1,111 | 4,002 | 2,524 | 1,038 | 108 | 9,259 | -57 | -28 | -704 | 22,964 | -17 | -0 |
Net increase (decrease) in cash and cash equivalents | |||||||||||||||||||||
6,883 | -22,575 | 11,829 | 4,780 | -10,436 | -144,727 | 134,896 | -1,746 | 27,368 | 6,420 | -826 | -965 | 1,283 | 20 | -2,105 | 1,201 | 3,190 | -1,371 | -7,357 | 9,170 | -428 | -100 |
Supplemental disclosure of non-cash investing and financing transactions | |||||||||||||||||||||
Shares issued | |||||||||||||||||||||
- | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 1,800 | - | - | - | - | - | - | - | - | - |
Unpaid deferred public offering and other financing costs | |||||||||||||||||||||
66 | - | - | - | - | - | -26 | 173 | 136 | -80 | 72 | 132 | 16 | - | -310 | -27 | 409 | - | - | - | - | - |
Repurchases of common stock | |||||||||||||||||||||
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1 |
Deferred IPO costs included in accounts payable and accrued expenses | |||||||||||||||||||||
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 189 |